| Electronic Medical Record-Based Nudge to Reduce SLNB (NCT06006910) | University of Pittsburgh Medical Center | 2021-10-15 |
| Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer (NCT05076695) | Fudan University | 2021-10-15 |
| Biology Guided Therapy for Breast Cancer for ER Positive (NCT04965688) | Inova Health Care Services | 2021-08-08 |
| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) (NCT04504916) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-10-07 |
| A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer (NCT03962647) | Vanderbilt-Ingram Cancer Center | 2019-07-08 |
| Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer (NCT03719495) | Duke University | 2019-06-19 |
| Personalised Disease Monitoring in Metastatic Breast Cancer (NCT04597580) | The Christie NHS Foundation Trust | 2019-05-08 |
| Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer (NCT03633331) | Alliance for Clinical Trials in Oncology | 2018-08-15 |
| Pre-operative Immunotherapy Combination Strategies in Breast Cancer (NCT03395899) | Queen Mary University of London | 2017-12-21 |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer (NCT03250676) | Eisai Inc. | 2017-08-23 |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (NCT02947685) | Alliance Foundation Trials, LLC. | 2017-06-21 |
| TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer (NCT02988986) | The Methodist Hospital Research Institute | 2017-04-24 |
| The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer (NCT03768479) | First Affiliated Hospital Xi'an Jiaotong University | 2017-03-05 |
| Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer (NCT02668666) | Oana Danciu, MD | 2017-02-01 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (NCT02957968) | Virginia Commonwealth University | 2017-01-24 |
| A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older (NCT02823262) | Beth Israel Deaconess Medical Center | 2016-07-01 |
| Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer (NCT02820961) | Syndax Pharmaceuticals | 2016-06-29 |
| Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer (NCT02186470) | Ohio State University Comprehensive Cancer Center | 2016-04-29 |
| [18F]FES PET/CT in Endocrine Refractory Breast Cancer (NCT02409316) | University of Pennsylvania | 2015-10-15 |
| A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers (NCT02238808) | AHS Cancer Control Alberta | 2015-08-01 |
| Patterns of Prescribing and Monitoring of Palbociclib (NCT03285568) | Rush University Medical Center | 2015-02-03 |
| Phase II Study of Everolimus Beyond Progression (NCT02269670) | Emory University | 2014-11-25 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (NCT02273752) | Emory University | 2014-11-01 |
| Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus (NCT02015559) | Jonsson Comprehensive Cancer Center | 2014-10-08 |
| Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors (NCT02235051) | City of Hope Medical Center | 2014-09-07 |
| Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer (NCT01992952) | Velindre NHS Trust | 2014-05-07 |
| Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery (NCT01953588) | Alliance for Clinical Trials in Oncology | 2014-02-27 |
| A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer (NCT02216786) | Queen Mary University of London | 2014-01-16 |
| FDG PET/CT in Breast Cancer Bone Mets (NCT01996046) | University of Pennsylvania | 2013-09-01 |
| REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy (NCT01984138) | Polly A. Niravath, MD | 2013-09-01 |
| A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) (NCT01824836) | ECOG-ACRIN Cancer Research Group | 2013-06-11 |
| BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (NCT01791478) | Vanderbilt-Ingram Cancer Center | 2013-04-01 |
| A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) (NCT02000375) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2013-03-01 |
| Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor (NCT01765049) | Seoul National University Hospital | 2013-01-01 |
| Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid (NCT01409811) | City of Hope Medical Center | 2012-09-14 |
| BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer (NCT01339442) | Washington University School of Medicine | 2011-11-14 |
| Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer (NCT01368263) | Washington University School of Medicine | 2011-09-01 |
| Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer (NCT01394211) | University of Arizona | 2011-07-13 |
| Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer (NCT01385280) | University of Arizona | 2011-02-01 |
| Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms (NCT01194440) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2011-02-01 |
| RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer (NCT01208441) | National Cancer Institute (NCI) | 2010-11-01 |
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene (NCT01219699) | Novartis Pharmaceuticals | 2010-10-05 |
| Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer (NCT01100489) | Case Comprehensive Cancer Center | 2010-02-01 |
| 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ (NCT00952731) | Northwestern University | 2009-12-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Breast Cancer Diet Intervention Study (NCT03886389) | Helse Stavanger HF | 2009-06-12 |
| F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer (NCT00602043) | National Cancer Institute (NCI) | 2008-09-01 |
| Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer (NCT00676663) | Syndax Pharmaceuticals | 2008-06-13 |
| Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer (NCT00194792) | University of Washington | 2005-08-01 |
| Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer (NCT00082810) | National Cancer Institute (NCI) | 2004-03-01 |
| Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (NCT00066690) | ETOP IBCSG Partners Foundation | 2003-12-17 |
| Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery (NCT00194779) | University of Washington | 2003-10-01 |
| Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer (NCT00003199) | Fred Hutchinson Cancer Center | 1997-11-01 |